Tezspire is a thymic stromal lymphopoietin (TSLP) inhibiting monoclonal antibody, which generated $86m in sales in 2023.

Radella Pharmaceuticals has reported topline outcomes from a Phase Ia trial that assessed an investigational therapy for ...

Lord Vallance stated the government sees investment, innovation, and public-private partnership as crucial to UK healthcare.

Treatments targeting alpha-synuclein aggregation account for 26% of the 7MM' pipeline disease-modifying therapies for ...

Minghui Pharmaceutical has reported promising initial outcomes from its Phase I trial of MHB039A to treat patients with solid ...

The former health minister predicted a bright future for UK trials and outlined steps to ensure clinical research thrives.

Penumbra has developed a microprocessor with thrombus removal algorithms that, combined with audio-visual feedback, help ...

Ionis has announced the design for a Phase III trial of ION582, a treatment for Angelman syndrome (AS), following discussions with the FDA.

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

The community screening programme charts an effective, affordable framework for TB control in the Canadian province of ...

Oak Hill Bio and Chiesi have enrolled the first European patient in a Phase IIb study for OHB-607, to prevent BPD in infants.